颐脑解郁方治疗肾虚肝郁型帕金森病抑郁的临床疗效评价及对血清DA、5-HT、NE的影响

doi:10.12092/j.issn.1009-2501.2018.04.012

中国临床药理学与治疗学 ›› 2018, Vol. 23 ›› Issue (4): 434-439.doi: 10.12092/j.issn.1009-2501.2018.04.012

颐脑解郁方治疗肾虚肝郁型帕金森病抑郁的临床疗效评价及对血清DA、5-HT、NE的影响

周荣，李玮，胡万华

浙江省温州市中医院神经内科，温州 325000，浙江

收稿日期:2017-09-07 修回日期:2017-10-13 出版日期:2018-04-26 发布日期:2018-04-13
通讯作者: 胡万华，男，本科，主任医师，研究方向：中西医结合神经内科。 Tel：13868601780
作者简介:周荣，男，硕士，主治医师，研究方向：中西医结合神经内科。 Tel：13868601780
基金资助:
浙江省中医药科学研究基金项目（2015ZA196）

Effects of Yinaojieyu prescription on the kidney deficiency and liver depression of Parkinson's disease and the effect on DA, 5-HT and NE in serum

ZHOU Rong, LI Wei, HU Wanhua

Department of Neurology, Wenzhou Hospital of Traditional Chinese Medicine, Wenzhou 325000, Zhejiang, China

Received:2017-09-07 Revised:2017-10-13 Online:2018-04-26 Published:2018-04-13

摘要/Abstract

摘要：

目的:探讨颐脑解郁方治疗肾虚肝郁型帕金森病抑郁的临床疗效评价及对血清DA、5-HT、NE的影响。方法:将60例肾虚肝郁型帕金森病抑郁患者分为研究组和对照组，每组30例。对照组采用帕罗西汀片治疗。研究组采用颐脑解郁方治疗。采用汉密顿抑郁量表（Hamilton Depression Scale，HAMD）评估患者的抑郁状态。采用统一帕金森病评定量表（Unified Parkinson's Disease Rating Scale，UPDRS）评估患者帕金森病的病情。采用世界卫生组织生活质量测定量表简明版（WHOQOL-BREF）评估患者的生存质量。检测两组患者治疗前后血清多巴胺（DA）、5-羟色胺（5-HT）、去甲肾上腺素（NE）的水平。结果:研究组的疗效高于对照组，但差异无统计学意义（P>0.05）；两组治疗后的HAMD评分、UPDRS评分明显降低，WHOQOL-BREF评分明显升高（P<0.05）；治疗后，研究组的HAMD评分、UPDRS评分低于对照组，WHOQOL-BREF评分高于对照组，差异有统计学意义（P<0.05）；两组治疗后的DA、NE、5-HT较治疗前均明显升高（P<0.05）；治疗后，研究组DA、NE、5-HT升高的程度优于对照组，差异有统计学意义（P<0.05）；两组不良反应发生率对比，差异无统计学意义（P>0.05）。结论:颐脑解郁方治疗肾虚肝郁型帕金森病抑郁的疗效确切，能提高DA、5-HT、NE的水平。

关键词: 颐脑解郁方, 帕金森病抑郁, 多巴胺, 5-羟色胺, 去甲肾上腺素

Abstract:

AIM: To investigate the clinical efficacy of Yinaojieyu prescription in the treatment of depression of kidney deficiency and liver depression type Parkinson disease, and to evaluate the effects of Yinaojieyu prescription on serum DA, 5-HT and NE. METHODS: Sixty patients with depression of kidney deficiency and liver depression type Parkinson disease were divided into the study group and the control group, 30 cases in each group. The control group was treated with paroxetine tablets. The study group was treated with Yinaojieyu prescription. Hamilton Depression Scale (HAMD) was used to evaluate the depressive state of patients. The Unified Parkinson Disease Rating Scale (UPDRS) was used to assess the condition of Parkinson's disease in the patient. WHO quality of life scale (WHOQOL-BREF) was used to assess the quality of life of patients with made. The levels of serum dopamine (DA), 5-serotonin (5-HT) and norepinephrine (NE) were measured before and after treatment in the two groups. RESULTS: The curative effect of the study group was higher than that of the control group, but the difference was not statistically significant (P>0.05); HAMD score and UPDRS score of the two groups after treatment were significantly decreased, while WHOQOL-BREF scores increased significantly (P<0.05); HAMD score and UPDRS score of the study group after treatment were lower than those of the control group; WHOQOL-BREF score was higher than that of the control group (P<0.05); The levels of DA, NE and 5-HT in two groups after treatment were significantly higher than those before treatment (P<0.05); after treatment, DA, NE, 5-HT of the study group increased as compared with the control group (P<0.05).No significant difference was observed of incidence of adverse reactions between the two groups (P>0.05). CONCLUSION: Yinaojieyu prescription is effective in treating Parkinson's disease with kidney deficiency and liver depression type, and can improve the levels of DA, 5-HT and NE.

Key words: Yinaojieyu prescription, Parkinson's disease, depression, DA, 5-HT, NE

中图分类号:

R965.2

周荣，李玮，胡万华. 颐脑解郁方治疗肾虚肝郁型帕金森病抑郁的临床疗效评价及对血清DA、5-HT、NE的影响[J]. 中国临床药理学与治疗学, 2018, 23(4): 434-439.

ZHOU Rong, LI Wei, HU Wanhua. Effects of Yinaojieyu prescription on the kidney deficiency and liver depression of Parkinson's disease and the effect on DA, 5-HT and NE in serum[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(4): 434-439.

参考文献

［1］刘娜. 帕金森病患者血尿酸的改变及其与抑郁、焦虑的相关性［J］. 实用临床医药杂志, 2014, 18(15):163.
［2］张海军. 帕罗西汀联合治疗帕金森病合并抑郁和焦虑症状的疗效分析［J］. 现代中西医结合杂志, 2015, 24(6):649-651.
［3］袁清洁, 刘岑, 曹克刚,等. 益肾疏肝法辨治帕金森病与抑郁共病40例临床观察［J］. 现代中医临床, 2014, 21(6):19-22.
［4］中华医学会神经病学分会运动障碍及帕金森病学组. 帕金森病治疗指南［J］. 中华神经科杂志, 2006, 39(6):409-412.
［5］中华医学会神经病学分会神经心理学与行为神经病学组. 帕金森病抑郁、焦虑及精神病性障碍的诊断标准及治疗指南［J］. 中华神经科杂志, 2013, 46(1):56-60.
［6］郑筱萸. 中药新药临床研究指导原则［M］. 北京：中国医药科技出版社, 2002:49-52.
［7］Hamilton M. Hamilton depression scale［M］. New York: Group, 2004:126-130.
［8］佚名. 统一帕金森病评定量表［J］. 中华老年医学杂志, 1999, 18(1):61-62.
［9］Nahler MPG. quality of life scale［M］//Dictionary of Pharmaceutical Medicine. Vienna: Springer, 2009:101-128.
［10］郑春叶, 雒晓东, 马丹丹,等. 柴甘解忧汤对帕金森病抑郁大鼠海马神经元及BDNF表达的影响［J］. 广州中医药大学学报, 2016, 33(1):84-87.
［11］宋春艳, 何丽华, 孙洪伟. 颐脑解郁方对冠心病伴抑郁患者的临床疗效观察［J］. 河北医学, 2016, 22(5):836-838.
［12］赵瑞珍, 唐启盛, 田青, 等. 颐脑解郁方对脑出血后抑郁大鼠核磁共振波谱的干预作用［J］. 中国科学:生命科学, 2016, 46(8):959.
［13］Broen MP, Moonen AJ, Kuijf ML, et al. Factor analysis of the hamilton depression rating scale in Parkinson's disease［J］. Parkinsonism Relat Disorders, 2015, 21(2):142-146.
［14］Menon B, Nayar R, Kumar S, et al. Parkinson's disease, depression, and quality-of-Life［J］. Indian J Psychol Med, 2015, 37(2):144.
［15］冼君定, 谭健烽, 万崇华,等. WHOQOL-BREF量表用于精神分裂症和抑郁症的信效度研究［J］. 中华疾病控制杂志, 2015, 19(5):500-503.
［16］Friedman AK, Walsh JJ, Juarez B, et al. Enhancing depression mechanisms in midbrain dopamine neurons achieves homeostatic resilience［J］. Science, 2014, 344(6181):313-319.
［17］池名, 青雪梅, 潘彦舒,等. 120例抑郁症患者大脑多神经递质变化初探［J］. 中国中药杂志, 2014, 39(8):1516-1524.
［18］Deurwaerdère PD, Ding Y. Antiparkinsonian treatment for depression in Parkinson's disease: Are selective serotonin reuptake inhibitors recommended ［J］. Trans Neurosci Clin, 2016, 2(2):138-149.

[1]	王娟, 刘维英, 叶育才, 付文丽, 张莎, 李乐萍. 去甲肾上腺素再摄取抑制剂联合抗毒蕈碱剂治疗阻塞性睡眠呼吸暂停的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(6): 714-720.
[2]	闫盼, 施剑飞, 李静, 王晟东, 王姝琪, 汪程鹏, 宋明芬. DRD2和5-HTR2A基因多态性及其交互作用对奥氮平治疗精神分裂症疗效的影响[J]. 中国临床药理学与治疗学, 2020, 25(10): 1131-1138.
[3]	林敏，沈仲夏，钱敏才，崔力军，任列，蔡敏，沈鑫华. 5-羟色胺转运体基因多态性与抗抑郁剂治疗广泛性焦虑障碍疗效的关联[J]. 中国临床药理学与治疗学, 2019, 24(8): 903-909.
[4]	陈连洲，李松华，蒲犇. 阿立哌唑联合草酸艾司西酞普兰对重度抑郁患者多巴胺、5-羟色胺和皮质醇的影响研究[J]. 中国临床药理学与治疗学, 2019, 24(4): 446-450.
[5]	葛波波，屈洪党，陈育华，胡彩彩，李理，姜牧君，许娟娟. 脂多糖诱导的慢性帕金森病小鼠模型α-突触核蛋白的出现和转移变化[J]. 中国临床药理学与治疗学, 2017, 22(3): 241-248.
[6]	蒙国懿，何繁漪，隋念含，赵林波，洪仕君，邢豫明，赵永娜. RGS4和D2受体信号通路相关分子在甲基苯丙胺依赖CPP大鼠纹状体的表达变化[J]. 中国临床药理学与治疗学, 2017, 22(12): 1377-1381.
[7]	易声华，李玉红，郑晓铸，安满丽，丁倩男，茹国美，张林. 血管活性药物对脓毒症羊乳酸林格氏液体动力学的影响[J]. 中国临床药理学与治疗学, 2017, 22(10): 1081-1089.
[8]	彭娟，黎翠林，刘剑秋，李智. 多巴胺D₁受体Ala229Thr多态性对受体信号转导功能的影响[J]. 中国临床药理学与治疗学, 2017, 22(10): 1106-1111.
[9]	高贵珍，吴超，薛宏宇，王超. 硫酸化茯苓多糖对MPTP诱导的小鼠多巴胺能神经元损伤的保护作用[J]. 中国临床药理学与治疗学, 2017, 22(1): 37-42.
[10]	顾钧, 徐泽民, 符丹, 周文华, 杨国栋. 东莨菪碱对吗啡诱导大鼠伏核多巴胺释放的调节作用[J]. 中国临床药理学与治疗学, 2015, 20(10): 1087-1091.
[11]	龙晓莉, 张遥衡, 卢卫琴, 凌泽毅. 去甲肾上腺素对人肺癌细胞株H460增殖、迁移和侵袭能力的影响[J]. 中国临床药理学与治疗学, 2014, 19(11): 1217-1221.
[12]	汪丽佳, 秦丽娟, 刘丹, 刘任, 周岐新. 大鼠抑郁行为的性别差异与单胺转运体及单胺氧化酶B关系的实验研究[J]. 中国临床药理学与治疗学, 2013, 18(9): 993-998.
[13]	颜默磊, 严静, 虞意华, 陈进, 蔡国龙. 多巴胺及去甲肾上腺素对脓毒性休克患者微循环的影响[J]. 中国临床药理学与治疗学, 2013, 18(5): 565-569.
[14]	谢建平, 任志斌, 马永春, 唐建良, 金卫东. 选择性5-羟色胺再摄取抑制剂联合丙戊酸钠缓释剂治疗伴激越、焦虑抑郁症的临床观察[J]. 中国临床药理学与治疗学, 2013, 18(1): 86-89.
[15]	吕亚囡, 董群. 大蒜素对不同年龄组小鼠血清神经递质5-羟色胺和β-内啡肽的影响[J]. 中国临床药理学与治疗学, 2012, 17(8): 884-887.

颐脑解郁方治疗肾虚肝郁型帕金森病抑郁的临床疗效评价及对血清DA、5-HT、NE的影响

Effects of Yinaojieyu prescription on the kidney deficiency and liver depression of Parkinson's disease and the effect on DA, 5-HT and NE in serum

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价